LEHI, Utah and LOUISVILLE, Ky., Nov. 26, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at two upcoming investor conferences:
Waystar will provide live webcasts of both events on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$36.45 |
Daily Change: | -0.26 -0.71 |
Daily Volume: | 1,088,216 |
Market Cap: | US$6.270B |
February 24, 2025 February 18, 2025 February 18, 2025 January 13, 2025 January 06, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load